Accelerate Your Drug Discovery & Development Programs with Confidence
Assays, Cell Lines, & Reagents: From Discovery to Commercial Release, Small & Large Molecules, Ready-to-use & Optimized Products
Developing small molecule and biologic therapeutics presents unique challenges at each development phase. This development requires the knowledge, experience, and a broad range of assays and reagents to understand the therapeutics' structure, activity, and mechanism of action (MOA). Eurofins DiscoverX® provides the most comprehensive portfolio of stable cell lines, validated functional and binding assay kits, recombinant proteins, and optimized reagents with these qualities developed and manufactured to support your drug discovery and development journey every step of the way. Several customized solutions can be delivered for program-specific needs by utilizing our deep expertise in cell line engineering, assay design, method qualification, and cell and protein production.
At Eurofins DiscoverX, we are committed to enabling and accelerating your multi-modality drug discovery and development programs from Discovery, through Development, and into Commercial Release & Stability. Discover for yourself how Eurofins DiscoverX enables you to accelerate your therapeutics development. Progress forward, confidently.
Product Highlights
- Enabling Technologies & Robust Assays – Improve productivity & effectiveness of your target validation, screening, lead optimization, & structure-activity relationships campaigns to accelerate the advancement of new therapeutics
- Comprehensive Portfolio – The industry's largest available portfolio of cell-based functional & binding assays, cell lines, and proteins covering the top therapeutic target classes including GPCRs, kinases, checkpoint & cytokine receptors, ion channels, & more
- Support Every Step of the Way – End-to-end support for your programs from discovery, through development, to commercial release & stability QC lot release testing
Supporting Your Journey with Cell-Based Assays and Capabilities for Characterization, Screening, Profiling, Potency, and Lot Release Programs
The Eurofins DiscoverX portfolio of high-quality products and custom assays enables you to expedite your research, and move your candidate through the drug discovery pipeline faster.
Global Programs using Eurofins DiscoverX Bioassays for Potency, Stability, and NAb Testing for Drug Release
Eurofins DiscoverX bioassays are fit-for-purpose for implementation in QC lot-release for potency testing, helping to accelerate the time-to-market for therapeutics by 6 to 9 months, and ensuring high lot-to-lot reproducibility and accuracy for the life of the program. These assays can be readily transferred and implemented in potency and stability programs that typically happen under GMP conditions at the sponsors’ testing sites or partner CRO/CDMO sites. Access off-the-shelf bioassay kits that have been successfully implemented in 100+ global programs covering popular and unique druggable target classes. NA = North America, EU = Europe, APAC = Asia Pacific, and NAb = Neutralizing Antibody.
The development of antibody-based therapeutics to target the killing of tumor cells has revolutionized the space of immuno-oncology and the…
Read MoreWith the increasing industry focus on antibody drugs, there is an ever-greater need for functional bioassays that interrogate the therapeutic…
Read MoreAn Application Note Assessing the Regulation of Mast Cell Function and its Implications in Safety Pharmacology. MrgprX2 antagonism promotes fresh…
Read MoreAn Application Note on automating Eurofins DiscoverX Cell-Based PathHunter® PD-1 Signaling Bioassay to bring high-throughput efficiencies to assay workflows. The…
Read MoreThrough early discovery, screening, characterization, and particularly for market release and commercialization of biologics, drug candidates require physiologically relevant, functional…
Read MoreAudrey B. Bergeron, B.A. and Hannah J. Gitschier, M.S. Corning Incorporated, Life Sciences Kennebunk, Maine
Read MoreSHP2 (Src-homology 2 domain-containing phosphatase 2) is a protein tyrosine phosphatase encoded by the human PTPN11 gene.SHP2 is a key…
Read MoreTherapeutics targeting glucagon-like peptide, GLP-1 and GLP-2, receptors are being developed to address globally prevalent medical disorders for managing diabetes,…
Watch NowBioassays are critical components of the quality control system for characterizing biologics. This roundtable involves an interactive panel discussion with…
Watch NowCOVID-19 has been declared a global pandemic by WHO. The disease is transmitted when the SARS-CoV-2 virus infects the respiratory…
Watch NowA quantitative and robust bioassay that is reflective of the MOA of the drug is a critical component of any…
Watch NowThe complex interactions between tumor cells and the host immune system are only beginning to be understood, however it is…
Watch NowWatch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed…
Watch NowWith the drug industry’s expanding emphasis on biologics, the need for robust cell-based assays has grown at all stages of…
Read MoreImmune checkpoint receptors play a key role in maintaining antitumor immunity, avert immunopathology, and modulate overall immune homeostasis. However, cancer…
Read MoreReady-to-Use qualified PathHunter® checkpoint bioassays are fit-forpurpose for potency testing for implementation in downstream development phases and Lot release of…
Read MoreTherapeutic regulators require assay data on the impact of Fc effector-mediated function of antibodies during their development as therapeutics. The…
Read MoreLearn how InCELL cell-based binding assays can be used to detect compound cell entry and engagement to specific targets including…
Watch NowLearn how PathHunter signaling reporter assays can be used to evaluate the cellular impact of therapeutics targeting a variety of…
Watch NowLearn about PathHunter Internalization assays developed to measure translocation of both single-pass and multi-pass receptors (like RTKs, checkpoint receptors and…
Watch NowLearn about PathHunter pharmacotrafficking assays to identify small molecule compounds that rescue disease relevant mutant membrane proteins like GPCRs, ion…
Watch NowLearn how functional cell-based assays support COVID-19 drug discovery programs, particularly in managing proinflammatory cytokines associated with high mortality rate…
Watch NowListen to the US PEGS 2023 conference talk by Venkatesh Chari, Ph.D. on MOA-reflective, functional cell-based assays (cell lines and…
Watch NowLearn about the first commercially available SIRPα/CD47 cell-based assay — PathHunter SIRPα Signaling Assay. Find out more about the generation…
Watch NowLearn about PathHunter® checkpoint receptor assays (cell lines and bioassays) for innate and adaptive immunity. Assays discussed include functional cell-based…
Watch NowLearn how KILR® cytotoxicity assays provide a simple, non-radioactive and dye free method to specifically measure target cell death in…
Watch NowLearn about Eurofins DiscoverX cell line engineering, assay development, and recombinant enzyme production custom capabilities. Find out more about cell…
Watch NowLearn about several GPCR assays and which ones to use and why for your research and drug discovery and development…
Watch NowPresenter: Jane Lamerdin, Ph.D., Director of R&D, Eurofins DiscoverX
Read MoreWatch Recorded Presentation Jane Lamerdin, Ph.D. Director R&D, Eurofins DiscoverX
Read MoreGaurav Agrawal, Ph.D.Scientific Development Manager Discover how cell-based assays and translational services accelerate cytokine-based immunotherapeutic development from early discovery to…
Read MoreGaurav Agrawal, Ph.D. Scientific Development Manager, Eurofins DiscoverX
Read MoreGaurav Agrawal, Ph.D. Scientific Development Manager, Eurofins DiscoverX
Read MorePresented by Dr. Alexander Baumann Head of European Business Development Eurofins DiscoverXProducts
Read MoreJennifer Lin-Jones, Ph.D. Senior Group Leader, Assay Development
Read MoreAndrew Green Senior Business Development Manager
Read MoreDiscoverX PEGS 2017 Presentation Presented By: Jane Lamerdin, Ph.D.
Read MoreGaurav Agrawal, Ph.D. Scientific Development Manager Abstract Millions of deaths worldwide have been attributed to COVID-19, caused by the SARS-CoV-2…
Read MoreGaurav Agrawal, Ph.D. Scientific Development Manager, Eurofins DiscoverX
Read MoreAlpana Prasad, Ph.D. Director, Innovations and Strategic Partnership
Read MoreVenkatesh Chari, Ph.D. Scientific Market Development Manager Eurofins DiscoverX Products LLC
Read MoreDenosumab (Prolia®) is a fully human sequence derived monoclonal antibody used for the treatment of osteoporosis in menopausal women via…
Read MoreOne of the major bottlenecks in the development of biosimilars is the need for good bioassays to create potency, stability…
Read MoreOne of the major bottlenecks in the development of biosimilars is the need for good bioassays to create potency, stability…
Read MoreNeutralizing antibodies (NAbs) to biological drugs may cause loss of therapeutic efficacy and in some cases, loss of endogenous protein…
Read MoreMonoclonal antibodies (MAbs) represent one of the fastest growing classes of biotherapeutic molecules today. While many technologies exist for generating…
Read MoreRegulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many…
Read MoreRegulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many…
Read MoreRegulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many…
Read MoreReporter genes are a well-established method used to develop cell-based assays for testing drugs that inhibit or activate targets involved…
Read MoreLigand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…
Read MoreInterleukins are known for their involvement in functioning of both the adaptive and innate immune systems. Interleukins direct immune cells…
Read MoreDiscoveRx® has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…
Read MoreDiscoveRx® has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…
Read MoreA common feature of 7TM receptors is that upon activation, the receptors are bound by cellular Arrestin proteins. DiscoveRx has…
Read MoreThere is an increasing need to generate therapeutics targeting metabolic and gastrointestinal diseases to address the global burden of metabolic…
Read MoreIt is well established that ligand binding can protect proteins from thermal denaturation in a cellular milieu; however, the broad…
Read MoreKinase targets have been extensively studied in biochemical assays using purified protein fragments for the kinase and the substrate. However,…
Read MoreBoth multi- and single-pass membrane receptors constitutively exhibit complicated and dynamic membrane receptor trafficking as well as internalization induced by…
Read MoreGlucagon-like peptides, GLP-1 & GLP-2, are well-researched, metabolically significant peptide hormones secreted from the L-cells of the small intestine in…
Read MoreGPCRs have long been regarded as a low-hanging fruit drug target as they are conveniently located on the cell surface…
Read MoreGlucagon-Like Peptide-1 (GLP-1), a member of the glucagon-secretin peptide family, is secreted from L-cells of the small intestine and binds…
Read MoreExplore GPCR-Ligand Interactions & Signaling Pathways with Binding & Functional Assays
Read MoreEurofins DiscoverX, in conjunction with Drug Target Review, sponsored and moderated a Bioassay roundtable discussion webinar with group leaders from…
Read MoreCytokines and their receptors have emerged as major drug targets for inflammatory and autoimmune diseases, allergies, and, more recently, in…
Read MoreThe COVID-19 pandemic has left us racing against time for remediation. As a result, we have witnessed hundreds of therapeutic…
Read MoreAs newer, cutting-edge therapeutic technologies emerge, an increasing need for rapid and reliable screening tools follows.
Read MoreAgonistic Antibodies and the Role of Checkpoint Receptors in Immune Function
Read MoreSeveral Bevacizumab products are approved for clinical use, with many others in late-stage clinical development worldwide. To aid the harmonization…
Read MoreWith the hope of discovering effective analgesics with fewer side effects, attention has recently shifted to allosteric modulators of the…
Read MoreThis article describes the finding of substantial upregulation of mRNA and enzymes of the cytochrome P450 1A family during a…
Read MoreA persistent problem in early small-molecule drug discovery is the frequent lack of rank-order correlation between biochemical potencies derived from…
Read MoreFYVE-type zinc finger-containing phosphoinositide kinase (PIKfyve) catalyzes the formation of phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) from phosphatidylinositol 3-phosphate (PI(3)P).
Read MoreG-protein-coupled receptors (GPCRs) have varying and diverse physiological roles, transmitting signals from a range of stimuli, including light, chemicals, peptides,…
Read MoreType 2 diabetes (T2D) affects Latinos at twice the rate seen in populations of European descent. We recently identified a…
Read MorePhosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are emerging as attractive therapeutic targets in diseases, such as cancer, immunological disorders, and neurodegeneration, owing…
Read MoreRobust & Reproducible Cell-Based Assays for Potency Testing
Read MoreFunctional Cell-Based Assays, Cell Lines, & Proteins for Cancer Research Improved or novel small molecule or biologic therapeutics for cancer…
Read MoreRobust Cell-Based Assays to Identify Therapeutic Hits Rapidly
Read MoreProducts & Custom Development Capabilities.
Read MoreAccelerate the Development of Peptide Therapeutics for Obesity & Diabetes With MOA-Reflective Assays — Assays for Screening, Profiling, Potency, &…
Read MoreComprehensive Eurofins DiscoverX product list to enable your drug discovery and development programs focused on checkpoint receptors, cytokine receptors/interleukins, cytotoxicity,…
Read MoreComprehensive Offering of Cellular Assays and Recombinant Enzymes for Drug Discovery Screening and Lead Optimization
Read MoreFunctionally validated ion channel products for drug discovery and safety pharmacology
Read MoreYour source for a complete offering of GPCR assays, cell lines, and membrane preps
Read MoreAccelerate your biologics development from discovery to QC lot release with cell-based assays. Comprehensive list of bioassay kits, cell lines,…
Read MoreExplore Functional Systems Driving GPCRs to the Forefront of Focused & Safe Therapeutics. Gain insights from industry experts on GPCR…
Read More
Program designed to qualify CRO/CDMOs to run Eurofins DiscoverX bioassays for client downstream therapeutic efforts
Read More
Ensure long-term assay reproducibility with the production of bioassay cells — critical reagents for cell banks
Read More
Custom cell lines, kits, assays, & protein development capabilities optimized to fit your requirements
Read More